Tick prevention debate sharpens around speed, duration, and compliance

A new Fear Free article is spotlighting a familiar but increasingly consequential issue in companion animal parasite control: how fast tick treatments work, and whether that speed holds over time. In a sponsored installment focused on preserving the human-animal bond, the publication pointed to a head-to-head lone star tick study in dogs and said lotilaner outperformed afoxolaner and sarolaner on both speed of kill and sustained efficacy. At roughly the same moment, the retail side of the market got its own tick-related update, with Tick Solutions Global announcing that its TiCK MiTT removal tool will roll out to more than 900 Petco stores in spring 2026. Together, the developments show how both veterinary and consumer channels are sharpening their focus on tick control as disease risk widens. (fearfree.com)

The backdrop is a tick-borne disease landscape that keeps getting more complicated. CAPC’s 2025 parasite forecasts say blacklegged ticks and lone star ticks are continuing to expand into new areas, while ehrlichiosis and anaplasmosis risk remains broad and, in many places, effectively year-round. CDC also says vector-borne diseases are an increasing threat in the U.S., with changing climate influencing the distribution and seasonality of ticks and the pathogens they carry. For veterinarians, that means the old seasonal prevention script is becoming less useful than region-specific, year-round planning. (capcvet.org)

Fear Free’s article focused on a study design using 32 dogs infested with 50 lone star ticks each, with treatment groups receiving lotilaner, afoxolaner, or sarolaner after ticks had attached and fed. According to the article, Credelio was the fastest among the three products and the only group to maintain at least 90% efficacy at every 24-hour assessment during the evaluation period. The publication also emphasized that lone star ticks are considered harder to kill than some other species, making them a meaningful challenge model, and noted that pathogen transmission can begin as early as 3 to 24 hours after attachment, depending on the organism. (fearfree.com)

That framing aligns with broader industry and research messaging, although the evidence base is fragmented and often brand-sponsored. Elanco has published a technical bulletin describing a head-to-head speed-of-kill analysis in lone star ticks for monthly isoxazolines, while Merck Animal Health has separately promoted published data showing strong initial and residual speed of kill for fluralaner against blacklegged ticks compared with sarolaner-based Simparica Trio. Older peer-reviewed studies also support the larger clinical point that speed matters because systemic isoxazolines require tick attachment and feeding before the parasite ingests the drug. In other words, “effective” is not a one-dimensional claim; species tested, time-to-kill endpoints, and duration claims all matter. (assets.elanco.com)

On the consumer side, TiCK MiTT’s Petco expansion is a reminder that tick management is also becoming a retail education story, not just a prescription or OTC drug story. Pet Age reported that Petco will carry an exclusive teal version of the reusable tick-removal product in more than 900 U.S. stores beginning in spring 2026. The product is positioned as a chemical-free way to remove loose ticks from fur, skin, and clothing before they embed. That may resonate with pet parents looking for visible, hands-on prevention steps, especially in high-risk regions, but it doesn’t change the underlying veterinary consensus that physical checks and removal tools should sit alongside, not in place of, preventive medication. (petage.com)

Why it matters: For veterinary teams, this story is really about decision-making and communication. CAPC says year-round use of products that kill and/or repel ticks is the baseline for parasite control programs, and it explicitly links those recommendations to both animal and human health. As tick ranges shift, clinics may need to revisit formularies, staff talking points, and client education materials so they address local species, expected transmission windows, adherence challenges, and whether a given product’s label and data match the clinic’s risk profile. The Fear Free piece also reflects how manufacturers are increasingly competing on comparative performance claims, which means clinicians may need to separate marketing language from study design, species specificity, and real-world fit for individual patients. (capcvet.org)

There’s also a One Health angle that may resonate with clients. CAPC notes that areas of canine risk often mirror human risk, and CDC says everyone in the U.S. is potentially exposed to vector-borne disease threats. That gives veterinarians a stronger platform to talk with pet parents about prevention as household risk reduction, not just pet comfort. In that context, faster kill claims may become more commercially important, but so will practical conversations about compliance, follow-through, and using adjunctive tools like tick checks and removal devices without giving clients a false sense that those measures alone are enough. (capcvet.org)

What to watch: Watch for more comparative efficacy messaging from manufacturers this year, possible follow-up content from Fear Free’s parasite series, and continued retail expansion of non-pharmaceutical tick products as clinics work to keep pet parents focused on layered, year-round prevention. (fearfree.com)